The retrospective cohort study, led by Stefani M. Doucette and senior author Abhay Lodha, examined the records of 676 extremely preterm infants born at less than 29 weeks’ gestational age. The researchers compared outcomes before and after their units introduced routine prophylactic arginine supplementation during the first 28 days of life. The primary outcome was bronchopulmonary dysplasia, defined as a continuing need for oxygen at 36 weeks’ postmenstrual age, with severity classified according to the evidence-based criteria developed by Jensen and colleagues. What the team found was striking: the incidence of any bronchopulmonary dysplasia fell from 85 percent to 73 percent after routine supplementation began, a drop of twelve percentage points in a population where nearly every infant had previously been expected to develop some degree of the disease.

Because a before-and-after comparison can be confounded by concurrent changes in care, the investigators went beyond raw numbers. Using multivariable regression analysis to adjust for other factors that influence lung outcomes, they calculated an adjusted odds ratio of 0.50 for any bronchopulmonary dysplasia, with a 95 percent confidence interval of 0.27 to 0.90. In practical terms, even after accounting for other variables, infants exposed to prophylactic arginine had roughly half the odds of developing the disease compared with those who did not receive it. The composite outcome of bronchopulmonary dysplasia or death before 36 weeks’ postmenstrual age was similarly reduced, with an adjusted odds ratio of 0.51 and a confidence interval of 0.28 to 0.91, suggesting that the benefit was not simply an artifact of shifting survival patterns.

Yet the story is not one of unqualified triumph. When the researchers looked specifically at severe disease, grades 2 and 3 on the Jensen scale, the protective signal disappeared. The adjusted odds ratio for severe bronchopulmonary dysplasia was 0.94, with a confidence interval spanning 0.41 to 2.14, a range that includes no effect at all. This pattern suggests that arginine supplementation may primarily prevent milder forms of the disease, or that the study, despite its respectable size, lacked the statistical power to detect a benefit against the most serious outcomes. The distinction matters enormously for families and clinicians, because severe disease carries the heaviest burden of long-term respiratory morbidity, neurodevelopmental impairment, and healthcare cost.

To understand why an amino acid might influence lung development at all, one has to look at the biochemistry of nitric oxide. L-arginine is the obligate substrate for nitric oxide synthase, the enzyme family that converts arginine into nitric oxide, a gaseous signaling molecule with profound effects on vascular tone. In the developing lung, nitric oxide promotes vasodilation of the pulmonary vasculature, supports endothelial function, and helps coordinate the intricate angiogenic crosstalk between blood vessels and the forming air sacs. Extremely preterm infants are known to have low circulating arginine levels, partly because arginine is consumed rapidly by the urea cycle and by arginase enzymes, and partly because the pathways that normally synthesize it are immature. When arginine availability falls, nitric oxide production falters, and the pulmonary vessels that should be remodeling and expanding instead constrict and develop abnormally.

This mechanistic framework is supported by decades of animal research. Studies in hyperoxia-exposed newborn rodents, a standard model of bronchopulmonary dysplasia, have shown that impaired nitric oxide signaling contributes to arrested alveolar growth and pulmonary vascular remodeling, and that restoring downstream intermediates such as L-citrulline can attenuate these injuries. Depletion of arginine by overactive arginase has been implicated in impaired relaxation of lung parenchyma in exposed neonatal animals. Clinical observations add further weight: neonates with pulmonary hypertension have been found to have abnormalities in urea-cycle intermediates and reduced nitric oxide production, linking arginine metabolism directly to pulmonary vascular disease in human newborns.

The arginine hypothesis also fits within a broader, and somewhat humbling, therapeutic history. Inhaled nitric oxide, the direct administration of the very molecule that arginine helps produce, has been tested extensively in preterm infants as a potential preventive therapy for bronchopulmonary dysplasia. Multiple randomized trials and an individual-patient-data meta-analysis failed to demonstrate a consistent benefit, and recent masked randomized controlled trials targeting early pulmonary hypertension have continued to yield uncertain results. The apparent failure of inhaled nitric oxide has pushed researchers toward upstream and systemic approaches, including enteral arginine supplementation, which is cheaper, easier to administer, and may support nitric oxide production throughout the body rather than only in the ventilated airways.

Interestingly, this is not the first time arginine has shown promise in neonatology. Earlier clinical work by some of the same Calgary investigators demonstrated that arginine supplementation could reduce the incidence of necrotizing enterocolitis, a devastating intestinal disease of prematurity, and an updated systematic review has supported that association. The common thread is nitric oxide biology: in the gut, nitric oxide maintains mucosal blood flow and barrier integrity, while in the lung it supports vascular and alveolar development. Arginine’s role as a shared substrate for these protective pathways has made it an attractive candidate for multi-target prophylaxis in the smallest infants, and the new findings extend that logic from the intestine to the lung.

The authors and independent observers alike caution that a retrospective, single-center before-and-after design cannot establish causation. Secular trends in neonatal care, including evolving ventilation strategies, caffeine use, surfactant protocols, and nutrition practices, could have contributed to the observed decline in disease rates, even with statistical adjustment. The study was approved by the Conjoint Health Research Ethics Board at the University of Calgary with a waiver of informed consent, and the authors declare no competing interests, but the inherent limitations of observational methodology mean that a randomized controlled trial remains the essential next step. Such a trial would need to be powered to detect effects on severe disease and long-term respiratory outcomes, not merely the milder spectrum of the condition.

Nevertheless, the implications of the study are considerable. Bronchopulmonary dysplasia remains one of the most common and consequential morbidities of extreme prematurity, imposing enormous healthcare burdens through prolonged hospitalization, home oxygen therapy, readmissions, and increased mortality in outpatient populations. If a randomized trial confirms the association reported here, neonatal intensive care units would gain a remarkably low-cost, orally administered preventive therapy that could be folded into existing feeding protocols for infants under 29 weeks. For now, the Calgary findings offer something rarer than a cure: a biologically plausible, mechanistically grounded lead in a field where genuine therapeutic advances have been scarce, and a reminder that sometimes the most powerful medicines are the humblest molecules already present in the body’s own chemistry.

Subject of Research: Prophylactic arginine supplementation to prevent bronchopulmonary dysplasia in extremely preterm infants

Article Title: The role of prophylactic arginine supplementation for prevention of bronchopulmonary dysplasia in extremely preterm infants

Article References: Doucette, S. M., Jain, S. K., Amin, H., Benlamri, A., Hussain, M., Tang, S., Bhandari, V., & Lodha, A. (2026). The role of prophylactic arginine supplementation for prevention of bronchopulmonary dysplasia in extremely preterm infants. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02922-4

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02922-4

Keywords: arginine supplementation, bronchopulmonary dysplasia, extremely preterm infants, nitric oxide, neonatology, retrospective cohort study, pulmonary vascular development, chronic lung disease, prematurity, Journal of Perinatology, role, prophylactic

The biological premise behind the device is elegant. Fetal skin does not mature in a linear fashion; instead, it follows a sigmoid trajectory, meaning that its structure and composition change dramatically and predictably across the course of gestation. As the fetus approaches term, the skin’s maturation alters the way it reflects light. A noninvasive optical sensor can detect these shifts in reflectance and translate them into an estimate of gestational age. Because the measurement is passive, painless, and requires no blood draw, no imaging equipment, and no specialized operator, it is precisely the kind of technology that could function in a birth center with no physician on site, or in a boat-accessed village where the nearest ultrasound machine is hundreds of kilometers away.

Why does gestational age matter so much? The answer, according to the research team led by Roberta Lins Gonçalves of the Federal University of Amazonas, lies largely in the respiratory system. Gestational age is the single most important factor for stratifying a newborn’s early respiratory risk. Babies born significantly preterm are at elevated risk of respiratory distress syndrome, a condition in which underdeveloped lungs lack sufficient surfactant and struggle to keep the air sacs inflated. Knowing whether a newborn is 32 weeks or 37 weeks along changes everything about how clinicians triage that infant: whether to monitor closely, whether to transfer to a neonatal intensive care unit, whether to prepare ventilatory support. Yet in resource-poor settings, the gold standard for dating a pregnancy, a first-trimester obstetric ultrasound, is often unavailable or unreliable, and the date of the last menstrual period is frequently uncertain or misremembered.

The APPLE study, whose name derives from the Portuguese phrase Acompanhamento de Bebês pelo PreemieTest, meaning follow-up of babies using the PreemieTest, will enroll newborns across a strikingly diverse network of birth settings in Brazil and Honduras. Participating sites include the Getúlio Vargas University Hospital in Manaus, the Sofia Feldman Hospital in Belo Horizonte, the Maria Aparecida Pedrossian University Hospital and the Florescer Humanized Birth Center in Mato Grosso do Sul, the Januário Cicco Maternity School and Ana Bezerra University Hospital in Rio Grande do Norte, and, crucially, the Vó Mundoca Hospital in Borba and the Edith Mendes Weckner Hospital in Novo Aripuanã, both riverside and remote municipalities in the Amazon. In Honduras, the study spans Hospital Escuela, the Instituto Hondureño de Seguridad Social, and Hospital General San Felipe in Tegucigalpa. This deliberate spread across tertiary hospitals, maternity schools, birth centers, and remote communities is the point: the researchers want to know not whether the device works in an idealized laboratory, but whether it works everywhere a baby might actually be born.

Methodologically, the validation is rigorous and multipronged. The gestational age estimated by PreemieTest will be compared against three traditional reference approaches: first-trimester ultrasound when available, which the researchers treat as the gold standard; the date of the last menstrual period; and a postnatal clinical score, a standardized assessment based on physical and neurological signs of maturity. Agreement between the device and these references will be quantified using correlation coefficients, Bland–Altman plots, which reveal whether a device systematically overestimates or underestimates across the measurement range, and concordance analyses. The team will also report the mean absolute error, a clinically intuitive metric that expresses, in weeks, how far off the device typically is. Performance will be examined across different skin phototypes, a critical consideration in a study population spanning the wide range of skin tones found in Brazil and Honduras, where pigmentation could plausibly influence optical readings if the algorithm were not properly calibrated.

What sets this study apart from a typical device-validation exercise is its longitudinal ambition. The researchers will follow the infants and model respiratory outcomes, including hospitalizations, clinical diagnoses, and the use of ventilatory support, at birth, three months, and six months of age. Using multivariable logistic regression adjusted for prespecified confounders such as birth weight, sex, prematurity, mode of delivery, and ultrasound-based gestational age, and accounting for clustering by study location, they aim to determine whether the device’s gestational age estimates actually predict clinically meaningful outcomes. This is the difference between a device that produces a number and a device that changes care. If optical gestational age assessment stratifies respiratory risk as well as ultrasound dating does, the case for deployment in low-resource settings becomes compelling.

The protocol also takes usability seriously, which is often the Achilles heel of medical devices intended for frontline use. Midwives, who in many of the participating settings are the primary birth attendants, will rate the device using the System Usability Scale, a validated instrument that yields a standardized score of perceived ease of use. A device that is accurate but cumbersome will simply not be adopted in a busy maternity ward or a community health post. By measuring usability alongside accuracy, the APPLE study is effectively testing the entire implementation pathway, not just the sensor. The study is registered in the Brazilian Clinical Trials Registry under RBR-10ch623r, was approved by ethics committees at all participating institutions in both countries, and will be conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from parents or legal guardians.

Data management reflects a similarly careful design. All information will be captured in Research Electronic Data Capture, the widely used REDCap platform, with standardized quality checks and continuous monitoring for completeness. Missing data, an inevitable feature of any study spanning the Amazon to urban Honduras, will be handled through multiple imputation and sensitivity analyses, so that the conclusions are robust to realistic imperfections in follow-up. The study is funded by Birthtech Dispositivos para a Saúde, the device’s manufacturer, together with Grand Challenges Canada, and supported by Brazilian federal agencies including CAPES, CNPq, and the Amazonas Research Foundation, a funding mix that pairs commercial development with public health philanthropy.

The stakes are enormous. The World Health Organization has long identified prematurity as the leading cause of death in children under five, and the first step in managing a preterm infant is knowing that the infant is preterm. In settings where early ultrasound is a luxury, clinicians currently rely on last menstrual period recall and postnatal scoring, both of which carry substantial error. A low-cost, handheld optical device that delivers a reliable gestational age estimate in the first day or two of life, across skin tones and across levels of care, would give midwives and physicians in the most remote corners of the world the same dating information that wealthy health systems take for granted. The APPLE study will not deliver that answer until its results are in, but its protocol, spanning the Amazon’s river communities to Tegucigalpa’s teaching hospitals, shows what honest, real-world validation of a global health technology looks like: diverse sites, hard reference standards, longitudinal outcomes, and a willingness to test whether a promising gadget survives contact with the places that need it most.

Subject of Research: Post-market validation of a portable optical device for newborn gestational age assessment

Article Title: APPLE study protocol: post-market validation of the PreemieTest® device for gestational age assessment in diverse birth settings

Article References: Gonçalves, R. L., da Costa Neto, S. S., de Souza, E. K. S., da Silva, A. V., Soares-Marangoni, D., Zambrano, L. I., Neves, G. S., Miralha, A. L., Lopes, T. C. P., de Andrade Vieira, J. A. R., da Silva, A. V., Costa, A. J. T., Lima, E. C. C., Bessa, N. B., Bahia, B. L., de Souza Rocha, P. G., de Sousa Júnior, F. S., Lima, J. C. B., Lima, H. L. O., … Pereira, S. A. (2026). APPLE study protocol: post-market validation of the PreemieTest® device for gestational age assessment in diverse birth settings. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07640-6

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07640-6

Keywords: gestational age, PreemieTest, prematurity, neonatal care, skin reflectance, optical device, Brazil, Honduras, Amazon, respiratory distress, global health, study protocol

Bronchopulmonary dysplasia, or BPD, is a chronic lung disease defined clinically by the continued need for respiratory support or supplemental oxygen at 36 weeks of postmenstrual age. It affects a substantial fraction of very preterm survivors and carries lifelong consequences, including increased risks of asthma-like symptoms, rehospitalization, impaired growth, and neurodevelopmental difficulties. The disorder arises from an intricate interplay of prematurity itself, inflammation, mechanical ventilation, oxygen toxicity, infection, and disturbed fluid homeostasis. Because the preterm lung must transition from a fluid-filled fetal state to an air-filled neonatal one within minutes to days, the way water moves into and out of the body during that transition has long been suspected to matter. Excess extracellular water can flood the pulmonary interstitium, worsen compliance, prolong the need for ventilation, and thereby amplify lung injury. This biological logic underpins the standard practice of restricting fluid intake and watching for a postnatal weight loss of roughly five to fifteen percent in the first week as a sign that the infant is clearing fluid appropriately.

The new study set out to characterize the longitudinal trajectories of fluid output, fluid balance, and related indicators across the first seven days of life, and then to test how those trajectories relate to moderate-to-severe BPD, classified according to the 2018 NICHD criteria. The investigators assembled a single-center retrospective cohort of very preterm infants who survived to 36 weeks postmenstrual age, and they applied generalized linear mixed models, a statistical framework well suited to repeated daily measurements nested within individual patients. This approach allowed them to compare day-by-day curves of fluid intake, output, balance, intake-to-output ratio, and weight loss between infants who later developed severe lung disease and those who did not, while adjusting for confounding factors. Their primary exposure was the cumulative fluid output over postnatal days three through seven, a window chosen because the earliest days are dominated by physiological transitions and measurement noise, whereas days three to seven better reflect sustained fluid handling.

Among the 211 infants included, 77, or 36.5 percent, developed moderate-to-severe BPD, a rate consistent with the substantial burden of disease in this gestational age range. When the daily trajectories were compared, one signal stood out: fluid balance over the first week behaved differently in the two groups, with a statistically significant BPD-by-time interaction for daily balance. Daily output, intake, intake-to-output ratio, and percentage weight loss did not differ significantly day by day between the groups. Yet when the researchers turned to cumulative measures across days three to seven, the pattern became sharper and, in one respect, inverted expectations. Every 10 milliliter per kilogram increase in cumulative fluid output over that five-day span was independently associated with higher odds of moderate-to-severe BPD, with an adjusted odds ratio of 1.073 and a 95 percent confidence interval of 1.031 to 1.115.

The crucial methodological move in the study was to separate output from intake. In observational neonatal data, output and intake are tightly coupled, because clinicians often adjust prescribed fluids in response to what the infant is losing, and because balance is by definition the arithmetic difference between the two. A naive analysis of net balance alone can therefore conflate the effects of giving too much fluid with the effects of losing fluid. The authors addressed this by constructing a joint model containing both cumulative output and cumulative intake over days three to seven. In that model, output retained a robust independent association with BPD, while cumulative intake was not statistically significant, with an adjusted odds ratio of 0.961 and a confidence interval of 0.924 to 0.999 that just crossed the null. A reference model using cumulative balance alone showed a reciprocal protective-sounding trend, with an adjusted odds ratio of 0.942, meaning a more positive balance appeared associated with lower odds of severe disease, a finding that is the mirror image of the output result and underscores how strongly the choice of exposure metric shapes conclusions.

That inversion is what makes the study provocative. Conventional neonatal teaching emphasizes cumulative net balance as the key target: a positive balance, meaning more fluid retained than excreted, is traditionally viewed as a risk factor for BPD because it implies pulmonary edema. The new data instead suggest that infants who went on to develop severe lung disease were, if anything, those with higher fluid losses in the first week, even after accounting for how much fluid they received. Several biological interpretations are possible, and the authors are careful to frame their findings as hypothesis generating rather than practice changing. High output could be a marker rather than a cause: infants who are sicker from the start, exposed to more inflammation or receiving nephrotoxic or diuretic medications, may both lose more fluid and be more likely to develop BPD for reasons unrelated to water handling. Alternatively, excessive fluid losses could reflect immature renal concentrating ability, and the resulting dehydration, electrolyte disturbance, and reduced circulating volume might impair perfusion and recovery of the developing lung.

There is also a plausible measurement story. Insensible water losses through the skin and respiratory tract of extremely preterm infants are enormous and difficult to quantify precisely, particularly under radiant warmers or phototherapy, and recorded output in retrospective chart data may miss stool losses or capture errors in weighing diapers. The daily trajectories analysis supports this caution: daily balance, a composite that integrates unmeasured losses implicitly, did show a significant group-by-time difference, while directly recorded daily output did not. Cumulative indices over days three to seven may smooth random error and reveal signal that single-day comparisons miss, but they also amplify any systematic bias in how fluids are charted. The single-center design, while ensuring consistent local practice, limits generalizability to centers with different fluid protocols, humidification strategies, or ventilation practices, and the retrospective nature means confounding by indication can never be fully excluded, even with statistical adjustment.

Statistically, the adjusted odds ratio of roughly 1.07 per 10 milliliters per kilogram is modest in magnitude but clinically meaningful when applied to the large fluid volumes handled over five days: a cumulative output difference of 100 milliliters per kilogram would translate into nearly a doubling of the odds in this model. Still, the confidence interval for intake came tantalizingly close to significance, and the reciprocal balance result suggests that the underlying associations are entangled in ways that only prospective, protocolized data collection can resolve. The study was retrospectively registered in the Chinese Clinical Trial Registry on 10 January 2025, and it was approved by the Institutional Review Board of Shanghai Children’s Medical Center with the consent requirement waived for the use of de-identified retrospective data. The authors declare no competing interests, and the work received no external funding.

For clinicians, the immediate takeaway is not to abandon careful fluid restriction but to pay closer attention to the output side of the ledger. Tracking cumulative output during days three to seven may offer an early window into which infants are at heightened risk of severe BPD, potentially prompting intensified respiratory care, closer renal monitoring, or earlier engagement of families in discussions about long-term follow-up. For researchers, the study identifies a clear agenda: prospective cohorts that simultaneously measure insensible losses, renal biomarkers, biompedance-based estimates of extracellular water, and echocardiographic markers such as hemodynamically significant patent ductus arteriosus, to determine whether high output is a cause, a consequence, or a correlated signature of lung vulnerability. Until such studies arrive, the authors’ message is measured but pointed. The neonatal fluid conversation has been dominated by how much fluid goes in; these findings insist that how much comes out deserves equal scientific scrutiny, and that the humble daily fluid chart, long treated as bookkeeping, may contain underexploited clues to one of prematurity’s most stubborn complications.

Subject of Research: Association of first-week fluid output trajectories with moderate-to-severe bronchopulmonary dysplasia in very preterm infants

Article Title: Association between fluid trajectories in the first postnatal week and moderate-to-severe bronchopulmonary dysplasia in very preterm infants: a retrospective cohort study

Article References: Wang, S., Chen, X., Bei, F., & Bu, J. (2026). Association between fluid trajectories in the first postnatal week and moderate-to-severe bronchopulmonary dysplasia in very preterm infants: a retrospective cohort study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07728-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07728-z

Keywords: bronchopulmonary dysplasia, fluid output, fluid balance, very preterm infant, neonatology, retrospective cohort study, fluid management, prematurity, chronic lung disease, postnatal fluid trajectories, Association, between